A Closer Look at 11 Analyst Recommendations For Intra-Cellular Therapies
Portfolio Pulse from Benzinga Insights
Intra-Cellular Therapies (NASDAQ: ITCI) received mixed analyst recommendations over the last quarter, with a majority being bullish. The average 12-month price target increased to $99.18. The company showed strong revenue growth but faces challenges in profitability and financial performance.
July 22, 2024 | 1:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Intra-Cellular Therapies received mixed analyst recommendations, with a majority being bullish. The average 12-month price target increased to $99.18. The company showed strong revenue growth but faces challenges in profitability and financial performance.
The majority of analysts are bullish on ITCI, and the average price target has increased, indicating positive sentiment. However, the company faces challenges in profitability and financial performance, which may temper the stock's short-term gains.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100